Revelation Biosciences Reports Positive PRIME Study Data for Gemini in CKD, Plans Pivotal AKI Trial
REVB is trading near its 52-week low of $1.11 (6.3% above the low) on light trading volume (0.1× avg).
Summary
Revelation Biosciences announced additional positive data from its PRIME clinical study for Gemini, its proprietary TLR4 agonist, in chronic kidney disease (CKD) patients. The data demonstrated Gemini's ability to durably normalize cellular inflammation and restore immunocompetence up to 7 days post-dose, with statistically significant reductions in inflammatory cytokines. This positive clinical development is highly material for Revelation Biosciences, a clinical-stage company with a very low market cap and a recent 10-K disclosing a going concern warning and significant delisting risk. The company also stated its intention to initiate a pivotal Phase 2/3 clinical study in Acute Kidney Injury (AKI) later this year, signaling crucial pipeline progression. Investors will now focus on the advancement of the AKI study and any related financing efforts.
At the time of this announcement, REVB was trading at $1.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.2M. The 52-week trading range was $1.11 to $44.77. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Access Newswire.